Historical source coverage
11 selected records with a cited source date in 2010. This archive is selective and does not imply continuous monitoring or complete historical coverage.
Literature metadata · Semax
PeptideScanner retained PubMed bibliographic metadata for PMID 11569188 at 2026-07-30T22:26:16.761Z. PubMed recorded a metadata revision date of 2010-11-18 and an Entrez history date of 2001-09-25. PeptideScanner associated this retained record with the identity slug semax. These dates describe PubMed metadata history, not the article's original publication date.
Source: PubMed ↗
Literature metadata · CJC-1295
PeptideScanner retained PubMed bibliographic metadata for PMID 15817669 at 2026-07-30T22:26:16.765Z. PubMed recorded a metadata revision date of 2010-11-18 and an Entrez history date of 2005-04-09. PeptideScanner associated this retained record with the identity slug cjc-1295. These dates describe PubMed metadata history, not the article's original publication date.
Source: PubMed ↗
Regulatory · Tesamorelin
The official Drugs@FDA dataset lists original submission 1 for BLA 022505 with status AP dated 2010-11-10, and names tesamorelin acetate among the application record's active ingredients.
Source: Drugs@FDA via openFDA ↗
Clinical trials · Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT00002881 at 2026-07-30T22:25:23.114Z. Its registry update date was 2010-11-09, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Clinical trials · Exenatide
PeptideScanner retained ClinicalTrials.gov record NCT01208649 at 2026-07-30T22:25:23.111Z. Its registry update date was 2010-09-24, and PeptideScanner's reviewed identity mapping was exenatide.
Source: ClinicalTrials.gov ↗
Literature metadata · Liraglutide
PeptideScanner retained PubMed bibliographic metadata for PMID 20861602 at 2026-07-30T22:26:16.803Z. PubMed recorded a metadata revision date of 2010-09-23 and an Entrez history date of 2010-09-24. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.
Source: PubMed ↗
Clinical trials · Teriparatide
PeptideScanner retained ClinicalTrials.gov record NCT00259298 at 2026-07-30T22:25:23.113Z. Its registry update date was 2010-08-11, and PeptideScanner's reviewed identity mapping was teriparatide.
Source: ClinicalTrials.gov ↗
Clinical trials · Octreotide
PeptideScanner retained ClinicalTrials.gov record NCT00005906 at 2026-07-30T22:25:23.111Z. Its registry update date was 2010-04-30, and PeptideScanner's reviewed identity mapping was octreotide.
Source: ClinicalTrials.gov ↗
Regulatory · Tesamorelin
The Federal Register published notice 2010-6169, attributed to FDA and its parent HHS department, on 2010-03-22. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Tesamorelin.
Source: Federal Register via GovInfo ↗
Regulatory · Liraglutide
The official Drugs@FDA dataset lists original submission 1 for NDA 022341 with status AP dated 2010-01-25, and names liraglutide among the application record's active ingredients.
Source: Drugs@FDA via openFDA ↗
Regulatory · Tesamorelin
The Federal Register published notice 2010-785, attributed to FDA and its parent HHS department, on 2010-01-19. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Tesamorelin.
Source: Federal Register via GovInfo ↗